Skip to content
Research Article Open access CC BY 4.0

Pantoprazole-Domperidone Induced Hyperprolactinemia and Galactorrhea in a Chronic Kidney Disease Patient on Dialysis

Deepak Kumar Chitralli, Anu Ann Abraham, Brian Mark Churchill, Rajeshwari Janakiraman

Asian Journal of Research in Nephrology · pp. 125–128 · Published 29 Dec 2021

Abstract

Pantoprazone-Domperidone fixed-dose combinations are commonly used in End Stage Renal Disease (ESRD) patients on dialysis. The medication helps in control of drug induced gastritis that can occur due to several medications including oral calcium and iron supplements. Besides this the pantoprazole-domperidone combination helps in treatment of uremic gastritis, peptic ulcer disease, and gastroesophageal reflux disease. Rarely, pantoprazole and domperidone may induce galactorrhea. We report a case of a female patient on dialysis who developed drug induced hyperprolactinemia and galactorrhea due to therapeutic dose of a fixed-dose combination of pantoprazole (40 mg) and domperidone (30 mg), used for treatment of gastritis- the duration of therapy being 4 months. Galactorrhea subsided after discontinuation of pantoprazole-domperidone.

Hyperprolactinemia galactorhea pantoprazole domperidone domperidone combination.

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.